These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28040354)

  • 1. Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Selinski S; Gerullis H; Otto T; Roth E; Volkert F; Ovsiannikov D; Salem J; Moormann O; Geis BC; Niedner H; Blaszkewicz M; Hengstler JG; Golka K
    Eur Urol; 2017 Jun; 71(6):994-995. PubMed ID: 28040354
    [No Abstract]   [Full Text] [Related]  

  • 2. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
    Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
    Coggon D
    Hum Exp Toxicol; 1995 Jun; 14(6):538-9. PubMed ID: 8519531
    [No Abstract]   [Full Text] [Related]  

  • 6. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
    Wu H; Wang X; Zhang L; Mo N; Lv Z
    Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
    Xu WJ; Wen LP; Jiang XX; Ye LY; Meng FH; Guan S; Qian YJ; Wei JF
    Clin Lab; 2017 Feb; 63(2):287-293. PubMed ID: 28182356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
    Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.
    Rothman N; Garcia-Closas M; Hein DW
    Int J Epidemiol; 2007 Feb; 36(1):23-8. PubMed ID: 17510073
    [No Abstract]   [Full Text] [Related]  

  • 11. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
    Hein DW
    Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
    Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
    Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyltransferase 1*10 genotype in bladder cancer patients.
    Höhne S; Gerullis H; Blaszkewicz M; Selinski S; Hengstler JG; Otto T; Golka K
    J Toxicol Environ Health A; 2017; 80(7-8):417-422. PubMed ID: 28696911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
    Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
    Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer.
    Deitz AC; Rothman N; Rebbeck TR; Hayes RB; Chow WH; Zheng W; Hein DW; García-Closas M
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1543-6. PubMed ID: 15342459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
    Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
    Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.